Aurinia Corp (AUPH) - Long-Term Debt to Capital Coefficient

The Aurinia Pharmaceuticals (AUPH) price chart illustrates the performance of the biopharmaceutical company that developed the first FDA-approved oral treatment for lupus nephritis, maintaining monopoly market access until the 2030s. The business's financial stability is supported by a steady cash flow of 0.06, which fully covers capital expenditures and debt. High barriers to entry are ensured by patent protection for dosages and the specific logistics required for patients with rare kidney diseases.

To identify the sector's fundamental leaders, the analyst evaluates balance sheet stability via the long-term debt-to-equity ratio. This metric measures the company's reliance on borrowed financing with maturities exceeding one year, which is critical for Aurinia Pharmaceuticals (AUPH) during business restructuring and share buybacks, as the long-term debt-to-equity ratio reflects the firm's ability to grow Lupkynis sales without the risk of default.